growth

Just wondering what people think about SIP about future growth. SIP has underperform in the past year, but with an ageing population and government spending accelerating in health care, wondering if SIP will be able to capitalise likle CSL.

I read an interesting article on "Business Spectator website" how a pharmaceutical company was going to double its revenue as follows:


"Teva Pharmaceutical Industries Ltd gained 4.4 per cent to $US59.34 a day after the world's largest generic drugmaker set a revenue target for 2015 of $US31 billion, more than than double its current annual amount."

Let hope SIP not just double its revenue but improve it return on equity.

DYOR